ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2020 - 2021)

ARS Pharmaceuticals has reported Amortization of Deferred Charges for 3 years, with the latest figure at $40000.0 in Q3 2022.

• Quarterly Amortization of Deferred Charges rose 107.1% year-over-year to $40000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2023 was $125000.0 (down 90.15% YoY) and the FY2021 annual result came in at $1.1 million, up 3596.77% from the prior year.
• Amortization of Deferred Charges grew to $40000.0 in Q3 2022 per SPRY's latest filing, from -$164000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $1.1 million in Q4 2021 and troughed at -$563000.0 in Q3 2021.
• A 3-year average of $118363.6 and a median of $249000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges soared 38033.33% in 2021, then tumbled 157.54% in 2022.
• Over 3 years, Amortization of Deferred Charges stood at $3000.0 in 2020, then jumped by 38033.33% to $1.1 million in 2021, then sank by 96.5% to $40000.0 in 2022.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $40000.0, -$164000.0, and $249000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.